Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

Anna Kuznetsova ¹

Aleksey Lebedev ¹

Konstantin Gromov ¹

Elena Kazennova ¹

Maurizio Zazzi ²

Francesca Incardona ^{3, 4}

Anders Sönnerborg ⁵

Marina Bobkova ¹

Hide authors affiliations

Gamaleya Centre for epidemiology and microbiology Moscow Russia |

University of Siena Siena Italy |

I‐PRO Rome Italy |

⁴

EuResist Network Rome Italy |

⁵

Karolinska Institutet Stockholm Sweden |

Publication type: Journal Article

Publication date: 2022-02-04

Wiley

Journal: Clinical Case Reports

SJR: —

CiteScore: —

Impact factor: 0.6

ISSN: 20500904

DOI: 10.1002/ccr3.5373

Copy DOI

PubMed ID: 35140966

General Medicine

Abstract

General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre-existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full virological efficacy for first-line RPV-based ART regimens.

By date By citations

	1 2 3
Viruses	Viruses, 3, 33.33% Viruses 3 publications, 33.33%
HIV Infection and Immunosuppressive Disorders	HIV Infection and Immunosuppressive Disorders, 2, 22.22% HIV Infection and Immunosuppressive Disorders 2 publications, 22.22%
AIDS Research and Human Retroviruses	AIDS Research and Human Retroviruses, 1, 11.11% AIDS Research and Human Retroviruses 1 publication, 11.11%
Tropical Medicine and Infectious Disease	Tropical Medicine and Infectious Disease, 1, 11.11% Tropical Medicine and Infectious Disease 1 publication, 11.11%
	1 2 3

	1 2 3 4
MDPI	MDPI, 4, 44.44% MDPI 4 publications, 44.44%
Baltic Medical Education Center	Baltic Medical Education Center, 2, 22.22% Baltic Medical Education Center 2 publications, 22.22%
Mary Ann Liebert	Mary Ann Liebert, 1, 11.11% Mary Ann Liebert 1 publication, 11.11%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 1, 11.11% Cold Spring Harbor Laboratory 1 publication, 11.11%
Central Research Institute for Epidemiology	Central Research Institute for Epidemiology, 1, 11.11% Central Research Institute for Epidemiology 1 publication, 11.11%
	1 2 3 4